Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-108 vs Levofloxacin 0.5% in cataract surgery
NCT02573610Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levofloxacin in postoperative endophthalmitis and Bacterial ocular infection (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change in the percentage of positive bacteriological test results at Day 0. Started Sep 2015; status: completed.
02
Drugs
levofloxacin
03
Conditions
postoperative endophthalmitisBacterial ocular infection
Beyond the preview
Go deeper on NCT02573610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573610.